ELVN — Enliven Therapeutics, Inc. stock price, charts and financials

QT90Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc. (NASDAQ: ELVN) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
59.42
-1.04-1.72%
OverviewShort InterestFilings
ELVNQT90Enliven Therapeutics, Inc.·NASDAQ
59.42-1.72%
TA
Loading chart...
Signal & projected range
Insider open-market saleHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
PRTC+4.51%$17.38CELC-2.14%$90.79DNTH+2.64%$111.80VKTX+0.53%$34.44ADPT+2.09%$25.45EWTX+2.44%$44.58DNLI+0.68%$25.00MANE-3.47%$110.42
Snapshot
Index-P/E-EPS (ttm)-Insider Own36.77%Shs Outstand71.44MPerf Week10.31%
Market Cap4.32BForward P/E-EPS next Y-2.22Insider Trans-5.69%Shs Float45.61MPerf Month15.87%
Enterprise Value4.19BPEG-EPS next Q-Inst Own-Short Float18.97%Perf Quarter50.06%
Income-114.46MP/S0.00EPS this Y-Inst Trans-Short Ratio6.60Perf Half Y124.01%
Sales0.00P/B4.47EPS next Y-25.33%ROA-11.64%Short Interest8.65MPerf YTD292.60%
Book/sh-P/C-EPS next 5Y-ROE-18.55%52W High61.25 -2.98%Perf Year220.91%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-13.88%52W Low14.54 308.79%Perf 3Y238.14%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility7.03% 5.22%Perf 5Y180.43%
Dividend TTM-EV/Sales0.00EPS Y/Y TTM11.64%Oper. Margin0.00%ATR (14)2.99Perf 10Y-
Dividend Ex-Date-Quick Ratio64.07Sales Y/Y TTM-Profit Margin0.00%RSI (14)70.73Recom2.00
Dividend Gr. 3/5Y-Current Ratio64.07EPS Q/Q33.33%SMA2010.71%Beta0.28Target Price73.40
Payout0.00%Debt/Eq0.00Sales Q/Q-SMA5025.10%Rel Volume0.49Prev Close60.46
Employees60LT Debt/Eq-0.06EarningsNov 11SMA20079.06%Avg Volume1.41MPrice59.42
IPO DateMar 12, 2020Option/ShortYes / YesEPS/Sales Surpr.14.34% -Net Debt/EBITDA1.27Volume696,061Change-1.72%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-06-26ReiteratedStifel Nicolaus$80 → $82
Aug-06-26ReiteratedGuggenheimBuy$80 → $78
Aug-06-26ReiteratedGoldman SachsBuy$67 → $80
Jul-21-26ReiteratedGoldman SachsBuy$59 → $67
Jul-09-26ReiteratedHC Wainwright & Co.Buy$39 → $65
Jul-01-26ReiteratedStifel Nicolaus$60 → $80
Jun-08-26InitiatedStifelBuy$60
Jun-02-26ReiteratedMizuhoOutperform$39 → $62
May-12-26InitiatedGuggenheimBuy$80
May-08-26ReiteratedGoldman SachsBuy$59
Latest News
Aug-06-26
Aug-06-2604:03AM
Dimensional Fund Advisors LP Raises Holdings in Enliven Therapeutics, Inc. $ELVNdefenseworld.net
Aug-05-26
Aug-05-2604:05PM
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Updateprnewswire.com
Aug-01-26
Aug-01-2603:50AM
Enliven Therapeutics, Inc. $ELVN is Avidity Partners Management LP’s 6th Largest Positiondefenseworld.net
Jul-21-26
Jul-21-2608:40AM
Goldman Sachs Maintains Buy on Enliven Therapeutics, Raises Price Target to $67Benzinga
Jul-09-26
Jul-09-2606:22AM
HC Wainwright & Co. Maintains Buy on Enliven Therapeutics, Raises Price Target to $64Benzinga
Jul-01-26
Jul-01-2610:02AM
Stifel Maintains Buy on Enliven Therapeutics, Raises Price Target to $80Benzinga
Jun-27-26
Jun-27-2603:36PM
What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%fool.com
12:03PM
What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rallyfool.com
Jun-22-26
Jun-22-2610:55AM
Enliven Therapeutics: Continuing The Pop Off; What Could Go Wrong?SeekingAlpha
Jun-15-26
Jun-15-2607:04PM
Enliven Therapeutics, Inc. (ELVN) Presents at European Hematology Association (EHA) 2026 Congress - SlideshowSeekingAlpha
Jun-12-26
Jun-12-2601:31AM
Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previously Treated Chronic Myeloid Leukemia - SlideshowSeekingAlpha
Jun-11-26
Jun-11-2602:42PM
Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previously Treated Chronic Myeloid Leukemia TranscriptSeekingAlpha
11:44AM
Crude Oil Edges Higher; Driven Brands Posts Upbeat EarningsBenzinga
10:10AM
Stitch Fix, Intel, KLA And Other Big Stocks Moving Higher On ThursdayBenzinga
08:57AM
Enliven Therapeutics Presents Data From The Phase 1 Enable Clinical Trial Evaluating ELVN-001 In Patients With Previously Treated Chronic Myeloid Leukemia; Notes Encouraging Efficacy Data By 24 WeeksBenzinga
Company

Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
FY 2017
12/31/2017
Total Revenue
000——————
Cost of Goods Sold Incl. D&A
000——————
Gross Profit
000——————
Selling, General and Administrative Excl. Other342419——————
Research and Development868165——————
Other Operating Expense-100——————
Operating Income-120-105-84——————
Interest Expense
000——————
Unusual Expense
—————————
Non-Operating Income (Expense)161612——————
Net Income Before Taxes-104-89-72——————
Income Taxes
000——————
Consolidated Net Income-104-89-72——————
Net Income From Continuing Operations-104-89-72——————
Net Income-104-89-72——————
EPS (Recurring)-1.83-1.89-2.01——————
EPS (Basic, Before Extraordinaries)-1.83-1.89-2.01——————
EPS (Diluted)-1.83-1.89-2.01——————
EBITDA-103-88-71——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio
—————————
Gross Margin
—————————
Operating Margin
—————————
Net Margin
—————————
Shares Outstanding574736——————
Market Capitalization8781,058498——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$68.01$53.07$38.13$23.18$8.24● Close Price0.00M13.13M26.26M39.38M52.51MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Derynck Mika KDirectorAug 04 '26Option Exercise10.84158,7951,720,967158,795Aug 06
Derynck Mika KDirectorAug 04 '26Sale60.21158,7959,561,5870Aug 06
Hohl BenjaminCHIEF FINANCIAL OFFICERJul 17 '26Option Exercise2.481,0722,65952,072Jul 21
Hohl BenjaminCHIEF FINANCIAL OFFICERJul 17 '26Sale52.646,018316,78046,054Jul 21
Collins Helen LouiseCHIEF MEDICAL OFFICERJul 17 '26Option Exercise2.485,00012,40030,000Jul 21
Collins Helen LouiseCHIEF MEDICAL OFFICERJul 17 '26Sale52.675,000263,37425,000Jul 21
Kunkel Lori AnneDirectorJul 06 '26Sale50.4910,000504,90341,884Jul 08
ORBIMED ADVISORS LLC10% OwnerJun 22 '26Sale45.36860,12339,014,045219,405Jun 24
Hohl BenjaminCHIEF FINANCIAL OFFICERJun 17 '26Option Exercise2.486,01814,92557,018Jun 22
Hohl BenjaminCHIEF FINANCIAL OFFICERJun 17 '26Sale43.806,018263,57751,000Jun 22
Collins Helen LouiseCHIEF MEDICAL OFFICERJun 17 '26Option Exercise2.485,00012,40030,000Jun 22
Collins Helen LouiseCHIEF MEDICAL OFFICERJun 17 '26Sale43.805,000219,01725,000Jun 22
ORBIMED ADVISORS LLC10% OwnerJun 15 '26Sale45.02281,40812,668,988245,728Jun 17
Kunkel Lori AnneDirectorJun 05 '26Sale34.5410,000345,35151,884Jun 09
Collins Helen LouiseCHIEF MEDICAL OFFICERMay 18 '26Option Exercise2.485,00012,40030,000May 20
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.